Blueprint Medicines Data Presented at 62nd ASH Annual Meeting and Exposition Highlight Broad Commitment to Advance Patient Care in Systemic Mastocytosis
- Monday, December 7, 2020, 8:03
- PR Newswire
- Add a comment
CAMBRIDGE, Mass., Dec. 7, 2020 /PRNewswire/ — Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced data from six oral and poster presentations highlighted at the virtual…
About the Author
admin has written 20655 stories on this site.